MDG1 MediGene AG

Medigene AG to participate in the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Medigene AG to participate in the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Planegg/Martinsried, March 19, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be participating in the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference on March 26, 2024.

Members of Medigene's management team will join a fireside chat and will be available for virtual one-on-one meetings with registered investors.

---  end of press release  ---

About Medigene AG

Medigene AG (FSE: MDG1) is an immuno-oncology platform company dedicated to developing differentiated T cell therapies for treatment of solid tumors. Its End-to-End Platform is built on multiple proprietary and exclusive technologies that enable the Company to generate optimal T cell receptors against both cancer testis antigens and neoantigens, armor and enhance these T cell receptor engineered (TCR) -T cells to create best-in-class, differentiated TCR-T therapies, and optimize the drug product composition for safety, efficacy and durability. The End-to-End Platform provides product candidates for both its own therapeutics pipeline and partnering. Medigene’s lead TCR-T program MDG1015 is expected to receive IND/CTA approval in the second half of 2024. For more information, please visit

 Medigene AG

Pamela Keck

Phone: 3 01

Email:

In case you no longer wish to receive any information about Medigene, please inform us by e-mail ( ). We will then delete your address from our distribution list.



EN
19/03/2024

Underlying

MDG1MediGene AG

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MediGene AG

 PRESS RELEASE
Free
MDG1 MEDIGENE AG

Medigene Files Patent for Unique NK-Specific TCR Construct with Europe...

Medigene Files Patent for Unique NK-Specific TCR Construct with European Patent Office (Medigene, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, today announced the submission of a patent for a novel natural killer (NK) cell-specific TCR construct to the European Patent Office. With that, Medigene is advancing its TCR-guided strategy by expanding the application of its proprietary 3S (sensitive, specific, and safe) TCRs into NK cells. This patent application marks a majo...

March 13, 2025 1 EN
 PRESS RELEASE
Free
MDG1 MEDIGENE AG

Medigene and EpimAb Biotherapeutics Enter into a Co-Development Partne...

Medigene and EpimAb Biotherapeutics Enter into a Co-Development Partnership for TCR-Guided T Cell Engagers  Planegg/Martinsried and Shanghai, February 27, 2025. Medigene AG (Medigene, FSE: MDG1, Prime Standard) and EpimAb Biotherapeutics, Inc. (EpimAb), announced that the companies have entered a strategic co-development agreement to research and develop off-the-shelf T cell receptor (TCR)-guided T Cell Engagers (TCR-TCEs) for the treatment of immune-related disorders, such as solid tumors. The multi-target collaboration combines the respective expertise of each company with Medigene’s 3S ...

February 27, 2025 1 EN
 PRESS RELEASE
Free
MDG1 MEDIGENE AG

Medigene AG Expands Patent Portfolio with Patent Grant for its JOVI Te...

Medigene AG Expands Patent Portfolio with Patent Grant for its JOVI Technology in the U.S. Planegg/Martinsried, February 19, 2025. (Medigene, FSE: MDG1, Prime Standard) , an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, announced today that the Company has been issued a patent by the U.S. Patent Office protecting its JOVI technology, a method allowing the enrichment of T cells using a specific anti-Cβ antibody. The U.S. patent for the JOVI technology was granted at the end of last year with the offi...

February 19, 2025 1 EN
 PRESS RELEASE
Free
MDG1 MEDIGENE AG

Medigene AG announces closing of its first SEPA tranche

Medigene AG announces closing of its first SEPA tranche Planegg/Martinsried, February 3, 2025. (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, announced the closing of its first tranche of the Standby Equity Purchase Agreement (“SEPA”) with a fund managed by Yorkville Advisors Global, LP (“Yorkville”) announced on January 24, 2024. The subscription price was set at EUR 1.70 and is equal to 95% of the average of the volume-weighted average pric...

February 3, 2025 1 EN
 PRESS RELEASE
Free
MDG1 MEDIGENE AG

Medigene AG Announces KRAS G12V as First Target for TCR-guided T Cell ...

Medigene AG Announces KRAS G12V as First Target for TCR-guided T Cell Engagers Planegg/Martinsried, December 9, 2024. (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, today announced the selection of Kirsten rat sarcoma viral oncogene homologue (KRAS) G12V, in the context of HLA*A11, as the initial target for the co-development of T cell receptor-guided T cell engagers (TCR-TCEs) with WuXi Biologics. The selection of this first target is a key...

December 9, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch